Latest France News

Medical Developments International (MVP) reports positive operating cash flow in H2 FY25, driven by strong Penthrox sales and strategic distribution shifts in Europe. The company eyes further growth amid regulatory progress and efficiency gains.

Apollo Minerals reports promising Phase 2 drilling results at its Salanie Gold Project in Gabon, revealing significant gold mineralisation and advancing exploration at its zinc and copper assets.

Atlas Arteria reported a robust 10.7% increase in Q2 2025 toll revenue, driven by strong traffic growth and toll hikes, while the French government reaffirmed its backing of the concession model with regulatory updates expected later this year.

PolyNovo Limited reports a robust FY25 with nearly 29% sales growth, a significant cash increase to A$33.5 million, and expanding global market presence. The company’s strategic investments and product innovations signal strong momentum ahead.

Zoono Group Limited reports strong progress in its shelf-life extension technology with 45 active trials worldwide and anticipates UK revenue by Q2 FY26 following successful supermarket partnerships.

Vulcan Energy Resources has raised €30 million through a strategic placement led by BNP Paribas’ Clean Energy Solutions Fund to advance critical development stages of its Phase One Lionheart lithium project.

Unith Limited reports a remarkable 1100% increase in users on its Digital Humans platform over the past year, driven by organic growth and strategic global partnerships. The company is poised to accelerate growth with upcoming marketing campaigns and high-profile industry events.

Vulcan Energy has extended its conditional debt commitment letter to September 2025, aligning with its revised financing timeline for the Lionheart Project. This move supports ongoing bank discussions and the potential inclusion of significant government funding.

Little Green Pharma invites shareholders to a detailed FY2025 financial results webinar, promising insights into profitability, revenue growth, and recent financing achievements.

National Australia Bank has updated key details on its 2025 interim dividend, including dividend reinvestment and bonus security plans, setting clear terms for shareholders ahead of the July payment.

Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.

National Australia Bank has updated its dividend announcement, confirming a fully franked ordinary dividend of AUD 0.85 per share for the half-year ending March 2025, payable in multiple currencies.